abstract |
The present invention relates to a pyranyl arylmethyl benzoquinazolinone compound of formula (I), which is a positive allosteric modulator of M1 receptors and can be effectively used in the treatment of diseases involving M1 receptors, such as Al Alzheimer's disease, schizophrenia, pain, or sleep disturbance. The present invention also relates to a pharmaceutical composition comprising the compound and the use of the compound and the composition in treating diseases mediated by M1 receptors. |